NCT01469572View on ClinicalTrials.gov

Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Pasireotide

Pasireotide is given as an injection.

PROCEDURE

Sir-sphere Radioembolization

A catheter will be placed in a branch of the hepatic artery (liver) that supplies the tumor with blood. Radioactive beads will be injected into the tumor through the catheter.

DRUG

Everolimus

Given orally every day for the duration of the study

Trial Locations (1)

30322

Emory University Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Emory University

OTHER